TenSixteen Bio is the first company to leverage somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. We are a precision platform therapeutics company utilizing novel genomic biology across multiple disease areas. TenSixteen was conceived around the promise of leveraging unique data assets and capabilities to drive discovery and novel clinical development paradigms, and we are building a genomics and data science platform that will enable data integration and generation to support these efforts. We aim to transform the future of precision medicine in complex diseases.​​



Join TechBio Companies Driving Patient Impact